



IMDRF International Medical Device
Regulators Forum


IMDRF GOOD REGULATORY REVIEW PRACTICES (GRRP) WORKING GROUP UPDATE

IMDRF GRRP Working Group Goals


- Develop documents focused on harmonizing marketing review requirements globally.
- Documents focus on:
 - Technical requirements for conducting marketing reviews
 - Competency requirements for marketing reviewers
 - Requirements for organizations performing marketing reviews



GRRP Documents



IMDRF GRRP WG/
N40 FINAL:2017
*Competence, Training,
and Conduct
Requirements for
Regulatory Reviewers*




IMDRF GRRP WG/
N47
FINAL: 2018
*Essential Principles of
Safety and
Performance*




IMDRF GRRP WG/
N52 FINAL: 2019
Principles of Labelling

Marketing Review Processes


GRRP Documents




IMDRF GRRP WG/
N59 FINAL:2020
*Requirements for
Regulatory Authority
Recognition of CABs*



IMDRF GRRP WG/
N61 FINAL:2020
*Assessment Methods
for Recognition of
CABs*



IMDRF GRRP WG/
N63 FINAL:2020
*Competence and
Training
Requirements for
Assessors of CABs*



IMDRF GRRP WG/N66
FINAL:2021
*Assessment and
Decision Process for the
Recognition of CABs
Conducting Medical
Device Regulatory
Reviews*


Recognition of Conformity Assessment Bodies (CABs)

Benefits of GRRP WG Documents

- Promote consistency, predictability and transparency in regulatory marketing review programs through agreed-upon sets of criteria and processes
- Provide confidence that marketing regulatory reviews conducted by CABs are rigorous enough to meet the requirements of Regulatory Authorities
- Provide opportunities for convergence of marketing review requirements
- Benefit all regulators, even those just starting to develop a regulatory medical device marketing review system

Current Work Item: N71 – Marketing Review Report Work Instructions

- Create a reporting template and work instruction to guide CABs in consistently evaluating marketing submissions and documenting their recommendations in marketing review reports
- Working group participation has expanded to include CAB representatives as observers



N71 Timeline

- **May 9, 2022** – Start of public comment period for N71 draft
- **July 8, 2022** – Public comment period closed
- **Present** – Reviewing comments
- **March 2023** – Expected time frame for publishing N71 in final

Thank you!

Questions?

Email kenneth.cavanaugh@fda.hhs.gov

Disclaimer

This document was produced by the International Medical Device Regulators Forum. There are no restrictions on the reproduction or use of this document; however, incorporation of this document, in part or in whole, into another document, or its translation into languages other than English, does not convey or represent an endorsement of any kind by the International Medical Device Regulators Forum.

Copyright 2021 by the International Medical Device Regulators Forum.